Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKB1MS30 ORD 6P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 12.38 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
0.00 0.00 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.00 -23.15 -8.43 27
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Amryt Pharma (AMYT) Latest News

More Amryt Pharma News
Amryt Pharma Takeover Rumours

Amryt Pharma (AMYT) Share Charts

1 Year Amryt Pharma Chart

1 Year Amryt Pharma Chart

1 Month Amryt Pharma Chart

1 Month Amryt Pharma Chart

Intraday Amryt Pharma Chart

Intraday Amryt Pharma Chart

Amryt Pharma (AMYT) Discussions and Chat

Amryt Pharma Forums and Chat

Date Time Title Posts
22/7/201909:04Amryt Pharma4,687
22/5/201919:19AMRYT Bio-Pharma R&D12
22/5/201919:18Amryt Pharma121
22/5/201919:18Amryt Pharma9

Add a New Thread

Amryt Pharma (AMYT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Amryt Pharma trades in real-time

Amryt Pharma (AMYT) Top Chat Posts

Amryt Pharma Daily Update: Amryt Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AMYT. The last closing price for Amryt Pharma was 12.38p.
Amryt Pharma Plc has a 4 week average price of 0p and a 12 week average price of 12p.
The 1 year high share price is 19.80p while the 1 year low share price is currently 12p.
There are currently 216,839,632 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Amryt Pharma Plc is £26,833,904.46.
papillon: There are 2 AMYT naysayers on the lse bb. Bronxville and radar. To be fair they have been consistent over the years. Neither hold AMYT shares, but were apparently shareholders in FAST and lost money as a result (perhaps a lot of money) and are very bitter towards AMYT as a result. Here's what radar posted late last night in response to a poster called chillipepper, who bought his shares back in the FAST O&G days and is down 90% on his investment and who wants to know what is going on with this takeover. I can't predict the future, but then neither can radar, or Bronxville. I can't trade AMYT shares until they relist so I will have to wait and see how things pan out. All I can do in the meantime is keep my fingers crossed!!!!!!!!!! radar Posts: 2,842 Opinion: No Opinion Price: 12.375 RE: info please Tue 23:23 The truthful answer to your question is, No, They cannot explain because they do not know, however they will give you waffle based on the triumph of their hope over actual and cold reality. They will give you an explanation crafted by what they want to say to make them feel important but devoid of reality. This is a pharma company that started out in oil. It has a name beginning with A so it’s near the start of the list of aim companies. If this is so good why then did the share price not go up before suspension ? Please don’t answer that question just think about it as this is not a forum for informed opinion or contribution. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Actually, radar, the share price did rise recently (look at the AMYT chart for May) on a few big buys before the small sellers appeared again. I suggested at the time that AMYT had been tipped, but it's obvious to me now that yesterday's news had leaked to a few individuals. That's the only way to explain the rise on no news. I suggest the non holding naysayers like Bronxville, radar, mdalos & purple keep schtum and wait and see how this pans out and the share price when AMYT eventually relists. If they are correct then they can shout out loud "I told you so" then, but until then give the AMYT knocking a rest, please!
papillon: Bronxville Posts: 712 Opinion: No Opinion Price: 17.10 RE: Rns Today 11:18 Based on the 2 RNS's I'm flummoxed as to why they thought the share price would rally above the 24 threshold. On reflection it would be extremely tough for 24 pence warrant holders to pony up again after Cathal Friel deleveraged at current levels. And what of the elusive Alan Harris's 8 million shares?? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> I presume that they must have thought that positive news on AP101 & AP103 (especially the former) would have pushed the AMYT share price above 24p, Bronxville. The AP101 news was issued to AMYT by a panel independent of AMYT. It's possible (maybe likely?) that AMYT were not expecting that this independent panel would want the trial size to be enlarged by 48 patients, Bronxville, when they changed the deadline for the warrants to be exercised from 31st December to 11th January in that 19th December RNS. There is no doubt that the enlargement of the AP101 phase III trial has curtailed PI's enthusiasm for AMYT. To get above 24p by Friday the big boys (II's) have to start buying now. And/or a preditor (such as Amicus) has to start buying a stake as a prelude to a take over offer in the future.
papillon: I hope you still don't hold FTC, bazworth. Currently down 55.8% at 7.95p today. That's what bad news does to a share price. I remember you saying you were bullish on FTC around 3 months ago and suggested we give it a look when the FTC share price had just peaked at 29p. A bearish Head & Shoulders pattern formed on the FTC chart in October at 20p. A similar 55% fall on a bad news RNS from AMYT next week would push the AMYT share price down to 7.90p. Fingers crossed we don't get bad news next week. I believe we'll get good news based on the history of AP101, bwtfdik? I have around £5.75k invested in AMYT. I've made my bet. I believe I've bet on an odds on favourite. Only time will tell.
papillon: That Sunday Times article: SABAH MEDDINGS: INSIDE THE CITY Amryt Pharma, the drugs minnow with big ambitions Sabah Meddings July 15 2018, 12:01am, The Sunday Times Music Health United States Pharmaceutical minnows are setting their sights on the 7,000 rare diseases for which there are often no cures ALAMY Share Save Once upon a time, the easiest way to make money in healthcare was to develop a remedy for heart disease or depression. Marginal improvements in patients’ symptoms meant the drugs company was on to a winner — a “blockbuster” product was within its grasp. Today a new band of pharmaceutical minnows are setting their sights on the 7,000 rare diseases for which there are often no cures. The regulatory process for getting these drugs to market can be quicker because this field is often ignored by the sector’s big players. One such company is Amryt Pharma, based in Dublin and listed on AIM. Founder and chief executive Joe Wiley conceived the idea of “commercialising” treatments for rare diseases that had been developed by others — thus removing the cost and risk of early-stage drug development. Amryt already has a product on the market in several countries. Last week, the company won approval for Lojuxta, a treatment for a rare genetic disorder that raises cholesterol levels, to be prescribed by the NHS. Amryt bought the rights to sell Lojuxta outside the US in December 2016. It has since grown sales from €7m to €12m (£10.6m). By 2023, they are expected to reach €34m. Here is where Amryt becomes more interesting. Analysts say the company’s 16p share price, which values it at £44.1m, is based on Lojuxta alone. However, Amryt has another treatment in development — and it is on the lookout for others. Interim analysis on Episalvan, which is currently in late-stage trials, is due to be published towards the end of this year. The gel is used to treat epidermolysis bullosa, a skin condition for which there is no cure. Those born with the disorder are known as butterfly children because everyday activities — even putting on socks — can cause extreme skin wounds. Episalvan is already approved to treat minor wounds in adults, but Amryt is testing it in what should be a more lucrative market. It is sensible to be cautious when investing in companies that have a long way to fall if their treatments fail to impress in clinical trials. Yet shares in Amryt have under-performed since it floated. Amryt has ambitious plans for Lojuxta, which it is expanding into other markets. Also, the company has the expertise of Harry Stratford, founder of biotech giant Shire, who is the chairman. If it continues to deliver on its promises and wins approval for Episalvan, Amryt should be an attractive long-term investment. Buy. @sabahmeddings hTTps:// PS Bermudashorts, you need to change the tt's to capital TT's (hTTp) otherwise the advfn sftware automatically changes the tt's to xx's so the link can't be accessed. PPS. I don't know how many share buying PI's investing in AIM shares read the Sunday Times, but it's likely the MM's will open the AMYT share price higher first thing Monday morning when the Mkt opens at 8am
papillon: "If the business's valuation is justified by Lojuxta alone then if AP101 fails the share price shouldn't fall in theory......but I suspect the share price will fall by between 30% and 50% at least initially." Analysts reckon the current AMYT Mkt Cap is "justified by Lojuxta alone", greendragon. They might be right, but then again they might be wrong. Don't forget some of those analysts receive money from AMYT, so they are not unbiased. There must be a signiicant portion of the current Mkt Cap attached to the EASE phase III trial so if analysts feel that the current Mkt Cap is "justified by Lojuxta alone" then either AMYT is seriously undervalued at the current Mkt Cap, or investors don't believe the analysts! I think you are correct in that if it's cosidered futile to continue with the EASE phase III trial then the AMYT share price will plummet. We wont know current Lojuxta revenue figures until the interim results are issued in September and the latest on the EASE phase III trial until October (probably). There's always the possibilty of a "wild card" RNS being issued between now and September concerning another Lojuxta type licensing deal. I have no idea of the likelihood that happening. It could be very low for all I know. As far as I'm concerned my circa £5k investment in AMYT is a punt. A gamble, but one I'm prepared to make. If the gamble comes off I'll be delighted; if it doesn't, that's life!
papillon: Bronxville Posts: 243 Off Topic Opinion: No Opinion Price: 17.35 RE: Friel's buy...32p in today's m..Today 00:00 £692,000 in Friels cold hard cash spent. Why is he selling at .17 now? Why Open Orphan? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> True, Bronxville, but what you're CONVENIENTLY FORGETTING is he only bought 2.6m AMYT shares @ 32p (via the 20.8m FAST shares he bought @ 4p) OUT OF A TOTAL of 33m AMYT shares he held until he sold 8.38m recently @ 17p. It's easy enough to check, but I suspect that FRIEL'S AVERAGE COST per AMYT share was MUCH LESS THAN 10p, Bronxville, since many of his 33m AMYT shares were acquired for NEGLIGABLE (or ZERO) cost due to his being one of the founders of AMYT. HENCE, Bronxville, I suspect Friel could sell ALL of his 33m shares @ 17p and still make a magnificent profit. I wouldn't be surprised if he doubled his money (at least) @ 17p compared to his AVERAGE buying price. You need to stop prattling on about the shares Friel bought @ the equivalent of 32p because it was only a small percentage of his 33m shares and the AVERAGE cost to him would likely be less than 10p. Lots of LOVE, papillon! :-) PS. I see Bronxville has filtered me. Not that I'm worried as I don't post on the lse bb's. PPS. Bronxville is digging up as much dirt as he can, even if the link to AMYT is tenuous. Good luck to him, because no one will take the slightest notice of him. NEWS drives share prices, not anonymous posters on bb's. Will the AMYT share price go towards £1, or 1p, during the next 12 months? IT ALL DEPENDS ON THE NEWS AMYT RELEASES AND WHETHER INVESTORS BELIEVE THAT NEWS, OR NOT. I can GUARANTEE that Bronxville will have absolutely NO influence on the direction of the AMYT share price over the next 12 months. Bronxville is SORE with Friel & AMYT because he bought FAST shares at a high price and consequently LOST a lot of his money when he bailed out of AMYT. That's understandable. He's a VERY SORE LOSER!
papillon: Bronxville Posts: 239 Off Topic Opinion: No Opinion Price: 17.35 A little memory loss Paps Today 21:35 11/8/2015 21:37 papillon: Friel could be feathering his nest, Asturius101, but he's showing a funny old way of going about it since he paid almost double the price recently to acquire over 18m FAST shares (he paid 4p per share when the then share price was 2.25p)!! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Sorry Bronxville. There's NOTHING wrong with my memory! However there is something wrong with yours! You're NOT using your little grey cells. Cathal Friel had just over 33m AMYT shares. He has sold 8.38m and now has circa 24.67m. Cathal Friel ended up with 39.75m shares in FAST in July 2015 after buying circa 20.85m FAST shares @ 4p (4p was then a very large percentage premium to the then quoted FAST sp). He bought those shares to stop the owners from blocking his bid to turn FAST into a biotech via an RTO. He had to pay way over the odds. I know all this because I bought my first FAST shares early in 2015 because of the large percentage discount that the shares were trading at compared to their cash. If you divide those 20.85m FAST shares by 8 you get the the equivalent number of AMYT shares that, in practice, Friel paid 32p for. That works out at circa 2.6m AMYT shares that, in effect, Friel paid 32p for. Yet until the start of this month Friel had just over 33m AMYT shares. Hence the AMYT shares he paid the equivalent of 32p for was less than 10% of his total holding!! Yet you, Bronxville, in your posts like to give the impression that all of Friel's AMYT shares cost the equivalent of 32p. WHY, is the question I ask? Is it because your memory is failing, or are you deliberately muddying the waters by giving a false impression? Even if you take the total number of FAST shares that Friel held (39.75m) and then convert them into AMYT shares (divide by 8) you get circa 5m AMYT shares. Yet Friel had just over 33m AMYT shares. Hence the total FAST shares held by Friel when converted into AMYT shares only comprised around 15% of his total holding in AMYT shares. In other words, Einstein (sorry, Bronxville) circa 28m of Friel's total holding of circa 33m AMYT shares (around 85%) had NO connection with his holding in FAST. So, in effect, Cathal Friel has sold 8.38m AMYT shares @ 17p from the 28m he acquired directly in AMYT (not via FAST). Some of those 28m shares were founders shares (and were no doubt acquired at no, or negliable, cost), whilst the remainder were acquired via the original placing. However members of the "concert party" (of which Friel was obviously one) did NOT pay 24p for their shares. They got their shares at a sizeable discount. Circa 16p was the price they paid. So by selling 8.38m AMYT shares @ 17p Cathal Friel has still made a profit (if the shares he sold could be considered to be "founders" shares then he made almost all profit because they were acquired at no, or negligable, cost to him). Presumably when he comes to sell his remaining 24.67m shares he will hope to make another profit. If the AMYT share price is above 32p when he next sells some (in 12 months time) he will definitely make a profit on them!!. :-) PS. You really must start posting the whole story, Bronxville and not just that part of the story that suits your agenda. You asked JimbobTechstock "You wouldn't happen to know (Cathal) personally would you." The funny thing is I was thinking of asking you the same question, but about Joe Wiley! LOL. I have wondered if you knew him and had a grudge against him. :-)
papillon: Bronxville Posts: 62 Off Topic Opinion: No Opinion Price: 20.125 RE: Wiley,Nealon Today 15:50 Yep the market is on to the sleezy antics of this management team. Options should have been at .30 cents.. Wiley basically just gave himself a £400 thousand bonus! For What? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> How has Wiley given himself a £400k bonus, Bronxville? Stop spouting unadultered rubbish. He HASN'T been given 2.061m shares. He's been given OPTIONS to acquire 2.061m shares. BIG DIFFERENCE. For all we know the AMYT share price will stay below the 20.12p subscription price (hope it doesn't, LOL) in which case he wont ever exercise that option to buy. This is AIM and AMYT still has a £55m Mkt Cap. There is NO guarantee that AP101 will be successful and there is NO guarantee that those who know how the phase 3 trial is progressing wont take advantage of that knowledge by selling, shorting, in the market. Not saying that will happen, but hey, who knows? I'm not against options per se, but the option price should have been much higher than the actual 20.12p. Perhaps 40p. That would have been an incentive. EDIT: For your information, Bronxville, Wiley will have received a £400k bonus from the BoD if the AMYT share price reaches 40p. Will it? Who can tell? I hope so, but I wouldn't bet my house on it happening. This is AIM after all and AMYT is very spculative. I've had a £4k gamble on AMYT, which I might push up to a maximum of £5k, but that's not definite. I definitely wouldn't go above £5k. I'm not rich enough to gamble more than £5k; after all I wouldn't bet £5k on a horse race, but some do!
papillon: Bronxville Posts: 21 Off Topic Opinion: No Opinion Price: 18.125 RE: Slide Today 15:12 Management are a disgrace... I have never seen so many rookie mistakes starting with the share price drop from .24 in the original reverse merger.Not to mention blatently misleading shareholders on companies valuation. Ineptitude!! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. LOL. Bronxville is the disgrace! Management are doing their job. The share price is dictated by short term traders! The job of management is to open up new markets for Lojuxta and progress the trials for AP101 & AP102. They seem to be doing that. Investors, especially short term traders, dictate the share price!!!!!!!!!! Obviously the recent placing was bad news for the AMYT share price in the short term. Why the BoD decided that the time was right to raise more cash is open to question. I don't think it affects AMYT prospects in the medium & longer term; Lojuxta sales and the trial results will determine the AMYT share price in the medium & longer term.
papillon: It's proving to be a very slow death for the AMYT share price in the continuing absence of good news (in fact any news!) from the company. I seem to remember the intraday low was around 14-14.25p back in early July. Will a retest of that low encourage bottom fishing buyers again, or will the AMYT share price continue it's descent into oblivion? Answers on a postcard please! LOL. Is AMYT worth a bottom fishing buy I wonder when it's below 15p?
Amryt Pharma share price data is direct from the London Stock Exchange
Your Recent History
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190722 09:44:28